Oncology and X-Ray products company
Varian Medical Systems
) recently revealed its latest EDGE radiosurgery suite, which is
a composite system for radiosurgery, utilizing management of
motion and tumor monitoring know how.
ACCURAY INC (ARAY): Free Stock Analysis
VARIAN MEDICAL (VAR): Free Stock Analysis
To read this article on Zacks.com click here.
The popularity of radiosurgery to treat cancer has been on the
rise. Radiosurgery utilizes complex hardware and software to
ablate tumors with strong radiation while reducing damage to
nearby normal cells.
The EDGE radiosurgery suite offers features such as numerous beam
configuring options, guidance of image, timely tools for
management of movement and the Eclipse software for planning
Medical practitioners based in the Champalimaud Foundation in
Lisbon, Portugal, along with other professionals, evaluated the
EDGE radiotherapy suite during its inception phase. The EDGE
radiosurgery suite is at present waiting for FDA 510 (k)
clearance and has not been commercialized.
Varian is a leading manufacturer of integrated radiotherapy
systems for cancer treatment and a premier supplier of X-ray
tubes for diagnostic imaging applications. The company operates
in a technology-driven environment where success depends on the
use of new technology, product development and upgrades. In the
radiation oncology market, Varian competes with
The company is poised to increase its market share in radiation
oncology. It currently enjoys a healthy demand for its coveted
TrueBeam technology, which has meaningfully contributed to its
net order oncology growth. Varian's TrueBeam was designed to
treat tumors with beams of high speed and precision. It
incorporates several technological innovations such as patient
positioning and managing his/her motion. TrueBeam can dispense
dosage roughly four times faster than that possible with its
Moreover, Varian enjoys a strong balance sheet marked by low debt
and moderate cash. The company from time to time uses a part of
its healthy cash flow for share repurchases.
Varian competes with larger players in a technology-intensive
industry. Further, uncertainties stemming from health care reform
and a still-weak hospital capital spending environment across
many developed countries, especially in Europe, are significant
We are currently 'Neutral' on Varian. The stock retains a Zacks
#3 Rank, which translates into a short-term Hold rating.